Senores Pharmaceuticals Limited develops and manufactures a range of pharmaceutical products primarily for the regulated markets of the US, Canada, and the UK, but it also serves emerging markets.
The company’s product portfolio consists of Amphetamine Sulfate Tablets, Hydroxychloroquine Sulfate Tablets, Ketoconazole Tablets, Butalbital, Acetaminophen and Caffeine Capsules, Mexiletine Hydrochloride Capsules, Ketorolac Tromethamine Tablets, Diclofenac Potassium Tablets, Diclofenac Potassium Tablets, Nicardipine Hydrochloride Capsules, Escitalopram Tablets, Prochlorperazine Maleate Tablets USP, Terazosin Capsules USP, Morphine Sulfate Tablets, Methadone Hydrochloride Tablets, Cyclobenzaprine Hydrochloride Tablets, Irbesartan Tablets, Risperidone Tablets Topiramate Capsules, and Ivermectin Tablets for regulated markets.
As of September 30, 2024, the company has launched 55 products in key therapeutic areas, including antibiotics and anti-fungal treatments. They have established partnerships with distributors and hospitals across several states in India.
As of September 30, 2024, the company operates three dedicated R&D facilities in India and the US. The company operates in Emerging Markets across 43 countries and manufactures critical care injectables and APIs.
The company’s manufacturing unit is situated in Ahmedabad, Gujarat.
Senores Pharmaceuticals IPO – Details
| IPO Opening Date | 20 December 2024 |
| IPO Closing Date | 24 December 2024 |
| Issue Type | Book Built Issue IPO |
| Issue Size | Total Issue Size: 1,48,87,723 Shares Worth ₹582.11 Crore Fresh Issue: 1,27,87,723 Shares Worth ₹500.00 Crore Offer For Sale: 21,00,000 Shares Worth ₹82.11 Crore |
| Face Value | ₹10 per equity share |
| IPO Price | ₹372 – ₹391 per share |
| Market Lot | 38 Shares |
| Min Order | 38 Shares (1 Lot) |
| Listing At | BSE, NSE |
| Register | Link Intime India Private Ltd |
| QIB Shares Offered | 75% |
| NII (HNI) Shares Offered | 15% |
| Retail Shares Offered | 10% |
Senores Pharmaceuticals IPO – Date Schedule
| IPO Open Date | 20 November 2024 |
| IPO Close Date | 24 December 2024 |
| Basis of Allotment | 26 December 2024 |
| Initiation of Refund | 27 December 2024 |
| Credit of Shares to Demat Account | 27 December 2024 |
| IPO Listing Date | 30 December 2024 |
| Cut-off time for UPI mandate confirmation | 5 PM on December 24, 2024 |
Senores Pharmaceuticals IPO – Lots Size & Price
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 38 | ₹14,858 |
| Retail (Max) | 13 | 494 | ₹1,93,154 |
| S-HNI (Min) | 14 | 532 | ₹2,08,012 |
| S-HNI (Max) | 67 | 2,546 | ₹9,95,486 |
| B-HNI (Min) | 68 | 2,584 | ₹10,10,344 |
Competitive Strengths
- The company serves the US, Canada, and the UK regulated markets with its US FDA-approved manufacturing facility.
- A unique product portfolio tailored for regulated markets developed in a brief period.
- Long-term marketing agreements with pharmaceutical companies in the US, Canada, and the United Kingdom regulated markets.
- Presence in the Emerging Markets with a product portfolio, including speciality or complex products.
- Robust R&D capabilities driving our differentiated portfolio of products.
- Experienced Management Team.
Company Promoters
- Swapnil Jatinbhai Shah
- Ashokkumar Vijaysinh Barot
Company Financials
| Particulars | Total Revenue | Total Expense | Profit After Tax | Total Borrowing |
|---|---|---|---|---|
| 31 March 2022 | 14.63 | 13.48 | 0.99 | 14.21 |
| 31 March 2023 | 39.02 | 26.58 | 8.43 | 60.76 |
| 31 March 2024 | 217.34 | 192.39 | 32.70 | 248.38 |
| 30 September 2024 | 183.35 | 153.95 | 23.94 | 242.03 |
Key Performance Indicator
| KPI | Values |
|---|---|
| ROE | 23.60% |
| ROCE | 11.73% |
| Debt/Equity | 1.07 |
| RoNW | 23.60% |
| PAT Margin | 15.25 |
| Price to Book Value | 5.84 |
| Pre IPO | Post IPO | |
| EPS (Rs) | 9.83 | 13.86 |
| P/E (x) | 39.77 | 28.21 |
Object Of The Issue
- Investment in one of the Subsidiaries, Havix Group, Inc. d/b/aAavis Pharmaceuticals(“Havix”), to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in the Atlanta Facility;
- Repayment/pre-payment, in full or in part, of certain borrowings availed by the Company;
- Investment in the Subsidiary, namely, Havix, for re-payment/pre-payment in whole or part of certain borrowings availed by such Subsidiary;
- Funding the working capital requirements of the Company;
- Investment in the Subsidiaries, namely, Senores Pharmaceuticals Inc. (“SPI”)and Ratnatris Pharmaceutical Private Limited (“Ratnatris”), to fund their working capital requirements.
- Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes.
Senores Pharmaceuticals IPO Peer Comparison
| S. No. | Face Value | Company Name | PE |
| 1 | 2 | Ajanta Pharma Limited | 43.34 |
| 2 | 2 | Alembic Pharmaceuticals Limited | 33.90 |
| 3 | 2 | Caplin Point Laboratories Limited | 40.84 |
| 4 | 1 | Gland Pharma Limited | 37.27 |
| 5 | 10 | Strides Pharma Science Limited | – |
Senores Pharmaceuticals IPO Promoter Holding
| Pre Issue Share Holding | 66.66% |
| Post Issue Share Holding | 45.76% |
Senores Pharmaceuticals IPO Prospectus
Company Contact Information
| Senores Pharmaceuticals Limited 1101 to 1103, 11th floor, South Tower, ONE 42 oppositeJayantilal Park, Ambali Bopal Road, Ahmedabad,-380054 Phone: +91-79-29999857 Email: cs@senorespharma.com Website: https://senorespharma.com/ |
Senores Pharmaceuticals IPO Registrar
| Link Intime India Private Ltd Phone: +91-22-4918 6270 Email: senorespharma.ipo@linkintime.co.in Website: https://linkintime.co.in/Initial_Offer/public-issues.html |
Senores Pharmaceuticals IPO Lead Manager(s)
| 1. Ambit Private Limited 2. Equirus Capital Private Limited 3. Nuvama Wealth Management Limited |
Senores Pharmaceuticals IPO FAQs
| What is Senores Pharmaceuticals IPO? Senores Pharmaceuticals IPO is a main-board IPO. The issue is priced at ₹372 to ₹391 per equity share. The IPO is to be listed on BSE & NSE. |
| When Senores Pharmaceuticals IPO will open? The IPO is to open on 20 December 2024 for QIB, NII, and Retail Investors. |
| What is Senores Pharmaceuticals IPO Investors Portion? The investors’ portion for QIB – 75%, NII – 15%, and Retail – 10%. |
| How to Apply the Senores Pharmaceuticals IPO? You can apply Senores Pharmaceuticals IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form. |
| How to Apply the Senores Pharmaceuticals IPO through Angle One? Log in to Angle One Application with your credentials. Select the IPO. You will see the IPO Name “Senores Pharmaceuticals IPO”. Click on Bid Button. Confirm your Application. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Angle One. |
| How to Apply the Senores Pharmaceuticals IPO through 5 Paisa? Log in to 5 Paisa Application with your credentials. Select the IPO. You will see the IPO Name “Senores Pharmaceuticals IPO“. Click on Bid Button. Confirm your Application. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with 5 Paisa. |
| How to Apply the Senores Pharmaceuticals IPO through Upstox? Log in to Upstox Application with your credentials. Select the IPO. You will see the IPO Name “Senores Pharmaceuticals IPO”. Click on Bid Button. Confirm your Application. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Upstox. |
| How to Apply the Senores Pharmaceuticals IPO through IIFL? Log in to IIFL Application with your credentials. Select the IPO. You will see the IPO Name “Senores Pharmaceuticals IPO“. Click on Bid Button. Confirm your Application. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with IIFL. |
| What is Senores Pharmaceuticals IPO Size? Senores Pharmaceuticals IPO size is ₹582.11 Crore. |
| What is the Senores Pharmaceuticals IPO Price Band? Senores Pharmaceuticals IPO Price Band is ₹372 to ₹391. |
| What is Senores Pharmaceuticals IPO Minimum and Maximum Lot Size for Retail? The minimum bid is 38 Shares with ₹14,858 amount while the maximum bid is 494 Shares with ₹1,93,154. |
| What is the Senores Pharmaceuticals IPO Allotment Date? Senores Pharmaceuticals IPO allotment date is 26 December 2024. |
| What is the Senores Pharmaceuticals IPO Listing Date? Senores Pharmaceuticals IPO listing date is 30 December 2024. The IPO is to be listed on BSE and NSE. |
